These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

409 related items for PubMed ID: 22853443

  • 1. Willingness to pay for diabetes drug therapy in type 2 diabetes patients: based on LEAD clinical programme results.
    Jendle J, Torffvit O, Ridderstråle M, Ericsson Å, Nilsen B, Bøgelund M.
    J Med Econ; 2012; 15 Suppl 2():1-5. PubMed ID: 22853443
    [Abstract] [Full Text] [Related]

  • 2. Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials.
    Wang B, Zhong J, Lin H, Zhao Z, Yan Z, He H, Ni Y, Liu D, Zhu Z.
    Diabetes Obes Metab; 2013 Aug; 15(8):737-49. PubMed ID: 23433305
    [Abstract] [Full Text] [Related]

  • 3. Cost-effectiveness of liraglutide versus rosiglitazone, both in combination with glimepiride in treatment of type 2 diabetes in the US.
    Lee WC, Conner C, Hammer M.
    Curr Med Res Opin; 2011 May; 27(5):897-906. PubMed ID: 21348806
    [Abstract] [Full Text] [Related]

  • 4. Economic outcomes of exenatide vs liraglutide in type 2 diabetes patients in the United States: results from a retrospective claims database analysis.
    Pelletier EM, Pawaskar M, Smith PJ, Best JH, Chapman RH.
    J Med Econ; 2012 May; 15(6):1039-50. PubMed ID: 22533526
    [Abstract] [Full Text] [Related]

  • 5. Liraglutide. Type 2 diabetes: more prudent to continue using exenatide.
    Prescrire Int; 2010 Jun; 19(107):109-12. PubMed ID: 20738033
    [Abstract] [Full Text] [Related]

  • 6. Cost-utility analysis of liraglutide versus glimepiride as add-on to metformin in type 2 diabetes patients in China.
    Gao L, Zhao FL, Li SC.
    Int J Technol Assess Health Care; 2012 Oct; 28(4):436-44. PubMed ID: 23006540
    [Abstract] [Full Text] [Related]

  • 7. Results of a model analysis of the cost-effectiveness of liraglutide versus exenatide added to metformin, glimepiride, or both for the treatment of type 2 diabetes in the United States.
    Lee WC, Conner C, Hammer M.
    Clin Ther; 2010 Sep; 32(10):1756-67. PubMed ID: 21194600
    [Abstract] [Full Text] [Related]

  • 8. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.
    Waugh N, Cummins E, Royle P, Clar C, Marien M, Richter B, Philip S.
    Health Technol Assess; 2010 Jul; 14(36):1-248. PubMed ID: 20646668
    [Abstract] [Full Text] [Related]

  • 9. A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus.
    Montanya E, Sesti G.
    Clin Ther; 2009 Nov; 31(11):2472-88. PubMed ID: 20109994
    [Abstract] [Full Text] [Related]

  • 10. Evaluating the long-term cost-effectiveness of liraglutide versus exenatide BID in patients with type 2 diabetes who fail to improve with oral antidiabetic agents.
    Valentine WJ, Palmer AJ, Lammert M, Langer J, Brändle M.
    Clin Ther; 2011 Nov; 33(11):1698-712. PubMed ID: 22018679
    [Abstract] [Full Text] [Related]

  • 11. The design of the liraglutide clinical trial programme.
    Nauck MA.
    Diabetes Obes Metab; 2012 Apr; 14 Suppl 2():4-12. PubMed ID: 22405264
    [Abstract] [Full Text] [Related]

  • 12. The cost-effectiveness of exenatide once weekly compared with exenatide twice daily and insulin glargine for the treatment of patients with type two diabetes and body mass index ≥30 kg/m(2) in Spain.
    Fonseca T, Clegg J, Caputo G, Norrbacka K, Dilla T, Alvarez M.
    J Med Econ; 2013 Jul; 16(7):926-38. PubMed ID: 23659201
    [Abstract] [Full Text] [Related]

  • 13. Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme.
    Niswender K, Pi-Sunyer X, Buse J, Jensen KH, Toft AD, Russell-Jones D, Zinman B.
    Diabetes Obes Metab; 2013 Jan; 15(1):42-54. PubMed ID: 22862847
    [Abstract] [Full Text] [Related]

  • 14. Liraglutide: from clinical trials to clinical practice.
    Gough SC.
    Diabetes Obes Metab; 2012 Apr; 14 Suppl 2():33-40. PubMed ID: 22405267
    [Abstract] [Full Text] [Related]

  • 15. Cost-effectiveness of exenatide twice daily vs insulin glargine as add-on therapy to oral antidiabetic agents in patients with type 2 diabetes in China.
    Gu S, Wang X, Qiao Q, Gao W, Wang J, Dong H.
    Diabetes Obes Metab; 2017 Dec; 19(12):1688-1697. PubMed ID: 28452095
    [Abstract] [Full Text] [Related]

  • 16. Exenatide BID and liraglutide QD treatment patterns among type 2 diabetes patients in Germany.
    Miller LA, Burudpakdee C, Zagar A, Bhosle M, Reaney M, Schabert VF, Bruhn D.
    J Med Econ; 2012 Dec; 15(4):746-57. PubMed ID: 22443463
    [Abstract] [Full Text] [Related]

  • 17. Cost-effectiveness of add-on treatments to metformin in a Swedish setting: liraglutide vs sulphonylurea or sitagplitin.
    Steen Carlsson K, Persson U.
    J Med Econ; 2014 Sep; 17(9):658-69. PubMed ID: 24950434
    [Abstract] [Full Text] [Related]

  • 18. Liraglutide for the treatment of type 2 diabetes.
    Shyangdan D, Cummins E, Royle P, Waugh N.
    Health Technol Assess; 2011 May; 15 Suppl 1():77-86. PubMed ID: 21609656
    [Abstract] [Full Text] [Related]

  • 19. Clinical studies of liraglutide, a novel, once-daily human glucagon-like peptide-1 analog for improved management of type 2 diabetes mellitus.
    Drab SR.
    Pharmacotherapy; 2009 Dec; 29(12 Pt 2):43S-54S. PubMed ID: 19947816
    [Abstract] [Full Text] [Related]

  • 20. Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes.
    Ray JA, Boye KS, Yurgin N, Valentine WJ, Roze S, McKendrick J, Tucker DM, Foos V, Palmer AJ.
    Curr Med Res Opin; 2007 Mar; 23(3):609-22. PubMed ID: 17355742
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.